Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced that it has entered into a definitive agreement to acquire GenVec, Inc. (NASDAQ: GNVC), a clinical-stage company and pioneer in the development of AdenoVerse™ gene delivery technology.
{iframe}http://www.prnewswire.com/news-releases/intrexon-to-acquire-genvec-to-expand-industry-leading-gene-delivery-platform-300395556.html{/iframe}